



GLAND PHARMA LIMITED

March 10, 2022

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; We would like to inform you that the Board of Directors (the “**Board**”) of Gland Pharma Limited (the “**Company**”) at its Meeting held today, i.e. Thursday, March 10, 2022 has *inter-alia* considered and approved the following:

I. Appointment of Directors

Based on the recommendation of Nomination and Remuneration Committee, the following appointments have been made:

1. Re-appointment of Mr. Srinivas Sadu (DIN: 06900659) as Managing Director and CEO of the Company for a period of 5 years, with effect from 25th April, 2022; subject to the approval of Members of the Company.
2. Appointment of Mr. Yao Fang (DIN: 09524705) as an Additional Director, categorized as Non-Independent and Non-Executive Director, with effect from March 10, 2022 as a Director liable to retire by rotation.

We also confirm that the Directors appointed are not debarred from holding the office of Director pursuant to any order of SEBI or any such other Authority.

II. Resignation of Director

3. Resignation of Mr. Li Dongming (DIN: 08047543) with effect from the conclusion of Board Meeting on March 10, 2022.

Disclosure pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed herewith as Annexure-A.

The Board Meeting commenced at 14.30 Hrs. IST and was concluded at 15.15 Hrs. IST.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary

Encl: As mentioned above

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIIIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999



ANNEXURE-A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015

Name of the Director: Mr. Srinivas Sadu
DIN: 06900659

S.No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Reappointed as Managing Director and CEO of the Company
2.	Date of appointment/ cessation (as applicable);	With effect from April 25, 2022
3.	Term of appointment;	Reappointed as the Managing Director & CEO for a tenure of 5 years, subject to shareholders approval.
4.	Brief profile (in case of appointment);	Attached as Annexure I
5.	Disclosure of relationships between directors (in case of appointment of a Director).	Mr. Srinivas Sadu is not related to any Director of the Company

Name of the Director: Mr. Yao Fang
DIN: 09524705

S.No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointed as an Additional Director, categorized as Non-Independent and Non-Executive Director, liable to retire by rotation.
2.	Date of appointment/ cessation (as applicable);	With effect from March 10, 2022.
3.	Term of appointment;	Not Applicable
4.	Brief profile (in case of appointment);	Attached as Annexure II
5.	Disclosure of relationships between directors (in case of appointment of a Director).	Mr. Yao Fang is not related to any Director of the Company



Name of the Director: Mr. Li Dongming
DIN: 08047543

S.No.	Particulars	Details
1.	Reason for change viz. appointment , resignation, removal, death or otherwise;	Resigned as Director of the Company
2.	Date of appointment /cessation (as applicable);	With effect from the conclusion of Board Meeting on March 10, 2022.
3.	Term of appointment;	Not Applicable
4.	Brief profile (in case of appointment);	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a Director).	Not Applicable



Annexure I

Name of the Director: Mr. Srinivas Sadu

DIN: 06900659

Date of Birth: 15-04-1969



Background:

Mr. Srinivas Sadu is the Managing Director and Chief Executive Officer of the Company.

He has deep insights and knowledge about the Pharmaceutical Industry and Global Generic Injectable Market. He is instrumental in expanding the business in USA, Europe and the Rest of the World Markets and in establishing world class manufacturing Facilities for the Company. Mr. Srinivas Sadu successfully introduced and implemented Co-marketing strategies in the Indian market with large Pharma majors and also established and expanded International Business Operations in more than 60 countries.

Mr. Srinivas Sadu has over 23 years of experience in business development, manufacturing operations, supply chain management and strategic planning. After working with Natco Pharma for a brief stint, he has been associated with Gland Pharma Limited for the last 22 years. He joined the Company as General Manager (Exports) in the year 2000 and later took roles of Senior General Manager (Exports), Vice-President (Exports) and Director (Business Development). He was also the Whole-time Director of the Company from June, 2014 to October, 2017. He was the Chief Operating Officer of the Company from April 30, 2011, to April 25, 2019. Mr. Srinivas Sadu was appointed as the MD and CEO with effect from April 25, 2019 for a period of three years.

Under Mr. Srinivas Sadu's leadership, the Company has in the last three years consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies.

As Gland Pharma's MD & CEO, Mr. Sadu's priorities have been the Company's strategic growth, strengthening the Company's presence in Rest of the World Markets, whilst maintaining its stronghold in USA; expansion of business into newer markets like China and new areas like Biosimilars CDMO; promoting strong relationships with business partners; and strong Business Development.

He holds a Bachelor's degree in Pharmacy from Gulbarga University; a Master's degree in Science from Long Island University, New York; and a Master's degree in Business Administration from University of Baltimore. He also holds a Post Graduate certificate in Finance and Management from the London School of Business and Finance.

Annexure II

Name of the Director: Mr. Yao Fang

DIN: 09524705

Date of Birth: 12-07-1969

**Background:**

Mr. Yao Fang is the Executive President of Fosun International Limited (listed on the Hong Kong Stock Exchange). Mr. Yao Fang joined the Fosun Group in April 2010 and he is also a Non-Executive Director of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., (listed on the Hong Kong Stock Exchange and the Shanghai Stock Exchange).

Prior to joining the Fosun Group, from 1993 to 2009, Mr. Yao Fang was successively the Assistant General Manager of the International Business Department of Shanghai Wanguo Securities Company Limited (now known as Shenyin & Wanguo Securities Company Limited), General Manager of Shanghai Industrial Assets Management Company Limited, General Manager of Shanghai Industrial Management (Shanghai) Company Limited, Managing Director of Shanghai Industrial Pharmaceutical Investment Company Limited (a company delisted from the Shanghai Stock Exchange), Chairman of Shanghai Overseas Company, Non-Executive Director of Lianhua Supermarket Holdings Company Limited (a company listed on the Hong Kong Stock Exchange), Executive Director of Shanghai Industrial Holdings Limited (a company listed on the Hong Kong Stock Exchange). Mr. Yao Fang was a Non-Executive Director of BioSino Bio-Technology and Science Incorporation (a company listed on the Hong Kong Stock Exchange) during 2011 to 2014.

Mr. Yao Fang obtained a bachelor's degree in Economics from Fudan University in July, 1989 and a Master's degree in Business Administration from The Chinese University of Hong Kong in December, 1993.
